Enveda Stock
| Valuation | $2B1 |
| Valuation Date | Sep 23, 2026 |
| Implied Valuation | n/a |
| Last Price | n/a |
| 52-Week High | n/a |
| 52-Week Low | n/a |
| YTD Return | n/a |
| 1-Year Return | n/a |
| 3-Year Return | n/a |
| Total Funding | $845M2 |
| Latest Round Amount | $311M2 |
| Latest Round | Series E |
| Funding Rounds | 10 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Enveda
Enveda is a clinical-stage biotechnology company that uses AI, metabolomics and automated labs to find small-molecule medicines in the chemistry of living organisms. Its platform catalogs the molecules in a natural sample and predicts their structures. It also tests what those molecules do, then turns the findings into its own drug candidates. Lead programs include ENV-294, an oral anti-inflammatory in Phase 2 trials for atopic dermatitis and asthma, and ENV-308, an oral metabolic pill designed to mimic a hormone the body releases during exercise. Enveda makes money by developing these internally discovered drugs and by partnering pipeline programs with pharmaceutical companies.
Invest in Enveda
Enveda is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Clarity (formerly Hiive).
Clarity is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on ClarityStock Analysis may be compensated for user sign-ups through Clarity links. Clarity is not affiliated with Stock Analysis. Securities offered by Clarity Capital Limited, member of FINRA/SIPC.
News
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda closed a $311 million Series E at a $2 billion valuation led by Catalio Capital Management, with participation from ICONIQ, Lightspeed, and others.
Enveda, an AI drugmaker, banks $311M in venture funding
The Boulder-based biotech said it will use the Series E proceeds to advance three clinical-stage drug candidates and expand its AI discovery platform.
Enveda Reports Positive Phase 1 Results for ENV-308, the First Pill Designed From the Chemistry of Exercise
Enveda said ENV-308 was well tolerated in 88 healthy volunteers, with no serious adverse events, and showed reductions in circulating leptin. The company plans Phase 2 studies testing whether the once...
Enveda’s Positive Phase 1B Results for ENV-294, a Potential First-in-Class Oral Therapy for Moderate-to-Severe Atopic Dermatitis, Were Presented at AAD Innovation Academy
Phase 1b data presented at the 2026 AAD Innovation Academy showed nine adults with moderate-to-severe atopic dermatitis had a mean 68% EASI reduction after 28 days of once-daily ENV-294, deepening to ...
The most innovative biotech companies of 2026
Fast Company ranked Enveda No. 5 among the most innovative biotech companies of 2026, citing its mass-spectrometry and AI platform and clinical progress across atopic dermatitis, asthma, IBD and obesi...
Enveda Advances Third Asset Into the Clinic as FDA Clears IND for ENV-6946 in IBD
The FDA cleared Enveda's IND for ENV-6946, a first-in-class oral IBD therapy, and the company initiated a Phase 1 trial, its third clinical program after ENV-294 and ENV-308.
Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946
The FDA cleared Enveda's IND for ENV-6946, an oral IBD candidate designed to hit multiple inflammatory pathways, and the company started a Phase 1 healthy-volunteer study. It is Enveda's third interna...
Enveda Announces US FDA IND Clearance and First Patient Dosed in Phase 1 Trial of ENV-308
Enveda received FDA clearance to start a Phase 1 study of ENV-308, an oral obesity candidate designed to mimic an exercise-related hormone, and dosed the first participant. Former Novo Nordisk executi...
Enveda Initiates Phase 2 Clinical Trials of ENV-294, a First-in-Class Oral Therapy in Atopic Dermatitis and Asthma
Enveda started two parallel Phase 2a trials of oral ENV-294 in moderate-to-severe atopic dermatitis and asthma. The company said interim Phase 1b data in dermatitis supported moving into both skin and...
Enveda Raises $150M Series D Funding to Reach Unicorn Status, Enrolls First Patient in Lead Program, and Adds Mikael Dolsten to Board of Directors
Enveda closed an oversubscribed $150 million Series D led by Premji Invest, bringing total funding to $517 million and unicorn status. It also enrolled the first patient in a Phase 1b trial of ENV-294...
Enveda Reports Favorable Phase 1 Safety for Novel Oral Anti-Inflammatory, Launches Phase 1b Trial in Atopic Dermatitis
ENV-294 completed a Phase 1a study in healthy volunteers with no dose-limiting toxicities or serious adverse events. Enveda said the safety review committee endorsed starting a Phase 1b trial in patie...
Enveda Gains Backing from Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M
BOULDER, Colo.--(BUSINESS WIRE)-- #AI--Sanofi invests in Enveda, reaffirming the industry's confidence in its AI drug discovery platform and ability to deliver differentiated medicines.
Enveda Expands into Asthma with First-in-Class Lead Asset ENV-294 and Assembles World-Class Advisory Board
Enveda named asthma as a second indication for ENV-294 based on preclinical and translational data. It also assembled an asthma advisory board chaired by Dr. Michael Wechsler of National Jewish Health...
Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates
Enveda raised an oversubscribed $130 million Series C led by Kinnevik and FPV, bringing total funding to $360 million. The round followed FDA IND clearance and the start of Phase 1 for lead program EN...
Enveda Announces First Candidate Discovered From Nature Using AI Advances to Clinical Trials
The FDA cleared Enveda's first IND, for ENV-294 in atopic dermatitis and other inflammatory conditions, and the company dosed its first Phase 1 patient in late October 2024. Enveda said it was the fir...
Enveda raises $55M to combine ancient remedies with AI for drug discovery
Enveda raised a $55 million Series B2 from Microsoft, Premji Invest, The Nature Conservancy and others, bringing total capital to $230 million. CEO Viswa Colluru said the company planned a Series C la...
Enveda Biosciences Announces Microsoft Collaboration and Reveals Foundation Model to “Read and Translate” Chemistry
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today a new collaboration with Microsoft and released...